XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Line Items]  
Summary of Common Stock Warrants Outstanding
The following table summarizes our common stock warrants outstanding at December 31, 2023 and 2022:
 
Issue Date
  
December 31,

2023
    
December 31,

2022
    
Exercise
Price
    
Termination
Date
 
6/10/2022
     4,848,963        4,939,515      $ 3.35        12/10/2027  
3/6/2023
     3,703,703        —       $ 3.78        3/6/2026  
Various 2020
     551,378        551,378      $ 3.99        ** 
12/1/2023
     1,411,769        —       $ 4.25        12/1/2026  
8/14/2020
     —         131,816      $ 4.67        8/14/2023  
8/25/2020
     1,873,622        1,873,622      $ 4.75        2/25/2024  
7/19/2019
     196,135        196,135      $ 5.76        7/8/2024  
12/1/2023
     211,569        —       $ 7.09        12/1/2026  
11/2/2018
     —         700,000      $ 7.16        11/2/2023  
  
 
 
    
 
 
       
     12,797,139        8,392,466        
  
 
 
    
 
 
       
 
**
A five-year term commences upon the earliest occurrence of either Trigger Date A or Trigger Date B. Trigger Date A is the date on which the Claimholder ceases the Subject Claim for any reason other than (i) a full and final arbitral award against the Claimholder or (ii) a full and final monetary settlement of the claim, see NOTE 12 Fair Value Financial Instruments – Litigation Financing. Trigger Date B is the date on which Proceeds are deposited into the Escrow Account.
Warrants [Member]  
Fair Value Disclosures [Line Items]  
Summary of Common Stock Warrants Outstanding
The Company’s oustanding and exercisable warrants as of December 31, 2023 are presented below:
 
Issue Date
   Exercise Price      Total
Warrants
Outstanding
     Exercisable
Warrants
Outstanding
     Expiration Date  
6/10/2022
   $ 3.35        4,848,963        4,848,963        6/10/2027  
3/6/2023
   $ 3.78        3,703,711        3,703,711        3/6/2026  
Various 2020
   $ 3.99        551,378        551,378       
**


12/1/2023
   $ 4.25        1,411,769        1,411,769        12/1/2026  
8/25/2020
   $ 4.75        1,873,622        1,873,622        2/25/2024  
7/19/2019
   $ 5.76        196,135        196,135        7/8/2024  
12/1/2023
   $ 7.09        211,570        211,570        12/1/2026  
     
 
 
    
 
 
    
        12,797,148        12,797,148     
     
 
 
    
 
 
    
 
**
A five-year exercise period commences upon the earliest occurrence of either Trigger Date A or Trigger Date B. Trigger Date A is the date on which the Claimholder ceases the Subject Claim for any reason other than (i) a full and final arbitral award against the Claimholder or (ii) a full and final monetary settlement of the claim, see Note 12 Fair Value Financial Instruments – Litigation Financing. Trigger Date B is the date on which Proceeds are deposited into the Escrow Account.
Schedule of company's fair value inputs
The Company’s fair value imputs of the warrants as of December 31, 2023 are presented below:
 
Issue Date
   Stock price      Exercise price      Term in years      Volitility    Treasury Yield  
6/10/2022
   $ 4.65      $ 3.35        5 years      62.8%      3.84
3/6/2023
   $ 4.65      $ 3.78        3 years      63.7%      4.61
12/1/2023
   $ 4.65      $ 4.25        3 years     
58.3%-59.9%
     4.31
12/1/2023
   $ 4.65      $ 7.09        3 years      58.3%-59.9%      4.31
Derivative liabilities [Member]  
Fair Value Disclosures [Line Items]  
Schedule of company's fair value inputs
The Company’s fair value imputs of derivative liabilities as of December 31, 2023 are presented below:
 
Issue Date
   Stock price      Exercise price      Term in years    Volitility     Treasury Yield  
6/29/2023
   $ 4.65      $ 3.70      0.75 year      59.5     5.0
6/4/2023
   $ 4.65      $ 4.40      1 year      66.9     4.8